TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16176051

Group type: EXPERIMENTAL
Intervention: Individuals with different forms of intersexuality
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Individuals with complete androgen insensitivity syndrome (CAIS)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Girls affected by congenital adrenal hyperplasia (CAH)
Number of subjects: 37
Study: 12843147

Group type: COMPARATOR
Intervention: AC2993 (synthetic exendin-4; exenatide) 0.1 micro g/kg, administered sc twice daily with meals for 5 days
Number of subjects: 37

Group type: COMPARATOR
Intervention: AC2993 (synthetic exendin-4; exenatide) 0.05, 0.1, or 0.2 micro g/kg, administered as a single dose following an overnight fast
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 10190914

Group type: EXPERIMENTAL
Intervention: Azlocillin and tobramycin (combination therapy)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Azlocillin alone
Number of subjects: 76
Study: 8664453

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 10

Group type: COMPARATOR
Intervention: Prostacyclin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Prostacyclin vs Sodium nitroprusside
Number of subjects: 10
Study: 2195226

Group type: EXPERIMENTAL
Intervention: Soft posterior chamber lens (IOGEL, Alcon) through a 6.5 mm scleral pocket incision
Number of subjects: 2

Group type: COMPARATOR
Intervention: IOGEL lens implanted through a 3.5 mm incision using a new instrument
Number of subjects: 2
Study: 844932

Group type: EXPERIMENTAL
Intervention: Pyridinolcarbamate (single intravenous administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyridinolcarbamate (6 months treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyridinolcarbamate
Number of subjects: 0
Study: 31825569

Group type: EXPERIMENTAL
Intervention: Tucatinib in combination with trastuzumab and capecitabine
Number of subjects: 612

Group type: COMPARATOR
Intervention: Placebo in combination with trastuzumab and capecitabine
Number of subjects: 612
Study: 31237718

Group type: EXPERIMENTAL
Intervention: Genetic predisposition to smoking initiation (ever smoking regularly) based on up to 372 single-nucleotide polymorphisms
Number of subjects: 34217

Group type: EXPERIMENTAL
Intervention: Genetic predisposition to smoking initiation (ever smoking regularly)
Number of subjects: 34217
Study: 28183071

Group type: EXPERIMENTAL
Intervention: Mind Sound Resonance Technique (MSRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (normal daily routines)
Number of subjects: 60
Study: 25979217

Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation (PTNS) in Group A (n = 11)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham treatment in Group B (n = 9)
Number of subjects: 20
Study: 22555780

Group type: EXPERIMENTAL
Intervention: Oral L-arginine supplementation (1.5 mmol kg(-1) per day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 21833652

Group type: EXPERIMENTAL
Intervention: Atorvastatin 160 mg 2 hours preoperatively and 24 hours post-surgery
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Atorvastatin 160 mg 12 hours preoperatively and 24 hours post-surgery
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard statin therapy (control)
Number of subjects: 101
Study: 18191322

Group type: EXPERIMENTAL
Intervention: Immediate androgen-deprivation therapy (ADT)
Number of subjects: 939

Group type: COMPARATOR
Intervention: Deferred androgen-deprivation therapy (ADT)
Number of subjects: 939
Study: 16843101

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate treatment for more than 1.5 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Untreated CML patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12771601

Group type: EXPERIMENTAL
Intervention: Gatifloxacin with interrupted tube feeds
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gatifloxacin with continuous tube feeding
Number of subjects: 16

Group type: COMPARATOR
Intervention: Gatifloxacin intravenous administration
Number of subjects: 16
Study: 10649150

Group type: EXPERIMENTAL
Intervention: Granisetron (40 microg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Droperidol (20 microg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Metoclopramide (0.2 mg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 120
Study: 9330921

Group type: EXPERIMENTAL
Intervention: Patient-counselor helping alliance (HA) measured at 1 and 3 months after admission
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Counselors' ratings of HA at 3 months
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: HA measures
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Controlling for urinalysis results in the previous month
Number of subjects: 57
Study: 8452114

Group type: EXPERIMENTAL
Intervention: MDL 72,222
Number of subjects: 24

Group type: COMPARATOR
Intervention: HDM
Number of subjects: 24
Study: 3017797

Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Propranolol (beta 1 + beta 2‐antagonist)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Metoprolol (beta 1‐antagonist)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 29333872

Group type: EXPERIMENTAL
Intervention: Unstable shoes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (regular shoes)
Number of subjects: 40
Study: 27439664

Group type: EXPERIMENTAL
Intervention: 940-nm diode laser
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gluma desensitizer
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 24925122

Group type: EXPERIMENTAL
Intervention: Sedentary time reduction in women (0.4 ± 1.2 h per day)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Sedentary time reduction
Number of subjects: 285
Study: 22542213

Group type: EXPERIMENTAL
Intervention: 10-day Foley catheterization
Number of subjects: 189

Group type: COMPARATOR
Intervention: 14-day Foley catheterization
Number of subjects: 189
Study: 20543309

Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation program using home tele-monitoring
Number of subjects: 0
Study: 18755101

Group type: EXPERIMENTAL
Intervention: Intervention group: yearly program with consultations every 15‐21 days, using a low calorie diet, prescribing physical exercise, changing of habits and health education.
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group: low calorie diet, seen 3 times/year.
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 169
Study: 15926182

Group type: EXPERIMENTAL
Intervention: Rough-surface stent
Number of subjects: 200

Group type: COMPARATOR
Intervention: Smooth-surface stent
Number of subjects: 200
Study: 12556096

Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate depot (3.75 mg every 28 days for 24 weeks)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Danazol (200 mg three times daily for 24 weeks)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 81
Study: 10516939

Group type: EXPERIMENTAL
Intervention: AMP 579 (150 micrograms/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7532254

Group type: EXPERIMENTAL
Intervention: Organs from anti-HCV positive donors
Number of subjects: 103

Group type: COMPARATOR
Intervention: Organs from anti-HCV negative donors
Number of subjects: 103
Study: 2390157

Group type: EXPERIMENTAL
Intervention: Intramuscular glucagon (1mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous dextrose (25g)
Number of subjects: 0
Study: 7011331

Group type: EXPERIMENTAL
Intervention: Org GC 94 (3 x 5 mg/day for 3 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (3 x 0.5 mg or placebo daily)
Number of subjects: 60
Study: 31564020

Group type: EXPERIMENTAL
Intervention: 40% oxygen
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 71
Study: 30209682

Group type: EXPERIMENTAL
Intervention: 6% NaOCl and 18% HEBP
Number of subjects: 100

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 100

Group type: COMPARATOR
Intervention: 6% NaOCl
Number of subjects: 100

Group type: COMPARATOR
Intervention: 17% EDTA
Number of subjects: 100

Group type: COMPARATOR
Intervention: 18% HEBP
Number of subjects: 100
Study: 29553543

Group type: EXPERIMENTAL
Intervention: Suprachoroidal autologous graft by Limoli Retinal Restoration Technique (LRRT) in group A (11 eyes).
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group B (14 eyes) with no intervention.
Number of subjects: 25
Study: 27270119

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with splinting
Number of subjects: 181

Group type: COMPARATOR
Intervention: Splinting alone
Number of subjects: 181
Study: 24568365

Group type: EXPERIMENTAL
Intervention: Silicon nitride cage
Number of subjects: 100

Group type: COMPARATOR
Intervention: PEEK cage
Number of subjects: 100
Study: 22270502

Group type: EXPERIMENTAL
Intervention: 4% amethocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 4% liposomal lidocaine
Number of subjects: 60
Study: 20976217

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulphadoxine‐pyrimethamine (IPTp‐SP)
Number of subjects: 0
Study: 16333818

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 16
Study: 16117182

Group type: EXPERIMENTAL
Intervention: L-lysine and L-arginine (3 g each/day) for 10 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 29
Study: 12407644

Group type: EXPERIMENTAL
Intervention: Dalteparin, 2,500 U
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enoxaparin, 40 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Danaparoid, 34 U/kg
Number of subjects: 21
Study: 9773701

Group type: EXPERIMENTAL
Intervention: Intravenous nalbuphine 60 microg/kg/h
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intravenous naloxone 2 microg/kg/h
Number of subjects: 75

Group type: COMPARATOR
Intervention: Intravenous saline infusion only
Number of subjects: 75
Study: 7812025

Group type: EXPERIMENTAL
Intervention: Intermittent treatment with 5‐ASA tablets (2.4 g for the first week of each month)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continuous treatment with 5‐ASA tablets (1.6 g each day)
Number of subjects: 50
Study: 3166357

Group type: EXPERIMENTAL
Intervention: Fish oil (12 1-g capsules daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (safflower oil)
Number of subjects: 18
Study: 29743598

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting prognosis of IgAN
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Urinary protein excretion (1‐3.5 g/d)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Urinary protein excretion (≥ 3.5 g/d)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: eGFR (G2)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: eGFR (G3)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: eGFR (G4)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: eGFR (G5)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Hyperuricaemia
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Mesangial proliferation
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Segmental glomerulosclerosis
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Tubular atrophy/interstitial fibrosis (T1)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Tubular atrophy/interstitial fibrosis (T2)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Crescents (C1)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Crescents (C2)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Glomerulosclerosis (25‐49%)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Glomerulosclerosis (≥ 50%)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Nomogram C-index
Number of subjects: 869
Study: 27138027

Group type: EXPERIMENTAL
Intervention: Hydrocodone ER 45 mg in subjects with varying degrees of renal impairment (study 1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Hydrocodone ER 15 mg in subjects with normal hepatic function or moderate hepatic impairment (study 2)
Number of subjects: 64
Study: 24417608

Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training (SCIT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 66
Study: 22365820

Group type: EXPERIMENTAL
Intervention: Intranasal administration of oxytocin (OT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 19796703

Group type: EXPERIMENTAL
Intervention: Stress (socially evaluated cold pressor test)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 48
Study: 19031757

Group type: EXPERIMENTAL
Intervention: Dietary modification
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Diet plus a supervised structured exercise program for 6 weeks (SE)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Diet plus a supervised structured exercise program for 1 year (CE)
Number of subjects: 78
Study: 15897717

Group type: EXPERIMENTAL
Intervention: Beer (4 units/day for men; 3 units/day for women)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Alcohol-free beer (4 units/day for men; 3 units/day for women)
Number of subjects: 19
Study: 15342612

Group type: EXPERIMENTAL
Intervention: Ibuprofen (initial dose of 10 mg/kg within 6 hours after birth, followed by two 5 mg/kg doses at 24-hour intervals)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Curative ibuprofen (same dosage regimen as prophylactic)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 12515150

Group type: EXPERIMENTAL
Intervention: milrinone
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 9059186

Group type: EXPERIMENTAL
Intervention: 5% albumin (group 1)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Isotonic saline (group 2)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study: 8299455

Group type: EXPERIMENTAL
Intervention: Regular insulin injected subcutaneously in the abdomen
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: NPH and regular insulins injected subcutaneously in the abdomen
Number of subjects: 22

Group type: COMPARATOR
Intervention: Regular insulin injected subcutaneously in the thigh
Number of subjects: 22

Group type: COMPARATOR
Intervention: NPH and regular insulins injected subcutaneously in the thigh
Number of subjects: 22
Study: 2868645

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 2604052

Group type: EXPERIMENTAL
Intervention: Nitrous oxide-oxygen sedation for 90 minutes followed by 100% oxygen for 2 minutes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitrous oxide-oxygen sedation for 90 minutes followed by 10 minutes of 100% oxygen
Number of subjects: 12

Group type: COMPARATOR
Intervention: 100% oxygen for 90 minutes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Room air for 90 minutes (baseline)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rating scale measurement for self-evaluation of alertness
Number of subjects: 12
Study: 29952663

Group type: EXPERIMENTAL
Intervention: Xalatan
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lataz
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Xalaprost
Number of subjects: 60
Study: 31813614

Group type: EXPERIMENTAL
Intervention: On-Idebenone (900 mg/day)
Number of subjects: 18
Study: 29953297

Group type: EXPERIMENTAL
Intervention: 1 ounce of an exogenous BHB solution (KETO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Noncaloric placebo (CON)
Number of subjects: 10
Study: 28854283

Group type: EXPERIMENTAL
Intervention: Transdermal rivastigmine (9.5 mg daily)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Lithium (400 mg twice daily, titrated progressively)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no new medication)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Transdermal rivastigmine
Number of subjects: 29
Study: 26044234

Group type: EXPERIMENTAL
Intervention: Single stent with high-pressure balloon inflation (Group A)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Single stent with high- and low-pressure balloon inflation at proximal and distal segment (Group B)
Number of subjects: 167
Study: 23680517

Group type: EXPERIMENTAL
Intervention: Barbed suture (Quill; Angiotech Pharmaceuticals, Inc.)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard suture (Vicryl; Ethicon Inc.)
Number of subjects: 63
Study: 21733822

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg bid for 6 months)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Baseline ratio of COX‐2 to 15‐hydroxyprostaglandin dehydrogenase mRNA in BAL cells
Number of subjects: 137
Study: 18696173

Group type: EXPERIMENTAL
Intervention: Combination resistance and balance-jumping training (COMB)
Number of subjects: 149
Study: 16914029

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids and/or long-acting beta-2-agonists
Number of subjects: 416

Group type: COMPARATOR
Intervention: No treatment (neither inhaled corticosteroids nor long-acting beta-2-agonists)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Advanced age, low FEV1, lower health status
Number of subjects: 416
Study: 15514271

Group type: EXPERIMENTAL
Intervention: (58)FeSO(4) + Na(2)EDTA
Number of subjects: 53

Group type: COMPARATOR
Intervention: (58)FeSO(4)
Number of subjects: 53
Study: 11712080

Group type: EXPERIMENTAL
Intervention: Comic film
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control film
Number of subjects: 21
Study: 9203100

Group type: EXPERIMENTAL
Intervention: ePTFE barrier membrane
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional control
Number of subjects: 10
Study: 8425035

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-trimester screening for Down syndrome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation of renal damage in fetuses with obstructive uropathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twin-to-twin transfusion syndrome
Number of subjects: 0
Study: 2959924

Group type: COMPARATOR
Intervention: Aminophylline (oral, sustained-release)
Number of subjects: 10
Study: 29878183

Group type: EXPERIMENTAL
Intervention: Favorable successful aging dimensions in vignettes
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Cognitive function
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Disability
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Disease
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Productive engagement
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Older respondents
Number of subjects: 2010
Study: 28506741

Group type: EXPERIMENTAL
Intervention: Refurbished two-bed ICU patient room with a new suspended wall-to-wall ceiling and a low frequency absorber
Number of subjects: 31

Group type: COMPARATOR
Intervention: Identical two-bed room (control) remained unchanged
Number of subjects: 31
Study: 28969697

Group type: EXPERIMENTAL
Intervention: Coaching combined with light therapy and pulsed electromagnetic field therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Coaching with the device turned off (Placebo group)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Coaching only (Control group)
Number of subjects: 96
Study: 26370187

Group type: EXPERIMENTAL
Intervention: sorafenib (400 mg, twice daily)
Number of subjects: 417

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 417
Study: 24217238

Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction with reduced maintenance immunosuppression
Number of subjects: 20
Study: 21752453

Group type: EXPERIMENTAL
Intervention: Seminal doses of buserelin acetate (5 μg) with varying sperm counts (6, 12, 24, 50, and 100 million total sperm in 0.5 mL)
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Seminal plasma dilutions (1/4 and 1/20) with 5 μg of buserelin acetate
Number of subjects: 751

Group type: COMPARATOR
Intervention: 1 μg of buserelin acetate administered intramuscularly
Number of subjects: 751
Study: 18251609

Group type: EXPERIMENTAL
Intervention: CO(2) laser therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nonirradiated control
Number of subjects: 90
Study: 16955427

Group type: EXPERIMENTAL
Intervention: Sertraline (treatment)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CSDD mood subscale (treatment)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: HDRS (treatment)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: NPI-M (treatment)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 44
Study: 14671530

Group type: EXPERIMENTAL
Intervention: Anesthetic pump placed in the subacromial space
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anesthetic pump placed in the glenohumeral joint
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10811042

Group type: EXPERIMENTAL
Intervention: CRP rapid test
Number of subjects: 812

Group type: COMPARATOR
Intervention: Control group (no CRP test)
Number of subjects: 812
Study: 8874332

Group type: EXPERIMENTAL
Intervention: Paclitaxel 125 mg/m2 over 24 hours followed by doxorubicin 48 mg/m2 over 48 hours
Number of subjects: 10

Group type: COMPARATOR
Intervention: Doxorubicin 48 mg/m2 over 48 hours followed by paclitaxel 125 mg/m2 over 24 hours
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Paclitaxel-doxorubicin sequence
Number of subjects: 10

Group type: COMPARATOR
Intervention: Doxorubicin-paclitaxel sequence
Number of subjects: 10
Study: 1989806

Group type: EXPERIMENTAL
Intervention: Fast Intralipid infusion (500 ml, 20 percent, infused over 5 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow Intralipid infusion (500 ml, 20 percent, infused over 10 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both fast and slow Intralipid infusion
Number of subjects: 0